This is a preview of subscription content, log in via an institution to check access.
Notes
Funded by Sun Pharmaceutical Industries, Inc.
Reference
Carrico J, et al. The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis. PharmacoEconomics-Open : 26 Mar 2020. Available from: URL: https://doi.org/10.1007/s41669-020-00208-9
Rights and permissions
About this article
Cite this article
Budget impact of introducing tildrakizumab for psoriasis treatment in US. PharmacoEcon Outcomes News 850, 8 (2020). https://doi.org/10.1007/s40274-020-6696-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6696-6